

# BIOSPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	14-Feb-2024	14-Feb-2027	: Date of Next Review
Prepared By:	Taylor Yurick	BSI-COA-0148 v.2.1	: Supersedes
QA/QC Approval:	Jessica DeMaio	Hannah Kuchmas	: Management Approval
Reason for Revision:	See Revision History in MasterControl.		

## CERTIFICATE OF ANALYSIS

### GUANIDINE HYDROCHLORIDE 6 MOLAR SOLUTION BIO EXCIPIENT GRADE / NEW CODE GHCL-3101-72 (HISTORICAL CODE GH3101-L200)

#### LOT: GHCL-L09-1224-0082

$\text{NH}_2\text{C}(\text{NH})\text{NH}_2\cdot\text{HCl}$  \* F.W. 95.53 g/mol. \* CAS# 50-01-1

Manufacturing Date: 12/11/24 Retest Date: 12/31/26

Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 12/13/24 Packaging Site: 100 Majestic Way, Bangor PA, 18013

ANALYSIS	SPECIFICATION	TEST RESULT	
Absorbance	260nm	0.1 a.u. max.	<0.1 a.u.
Appearance and Color	Clear, Colorless Liquid	Clear, Colorless Liquid	Clear, Colorless Liquid
Cyanide	Passes Test	Passes Test	Passes Test
Heavy Metals	≤ 10 ppm	<10 ppm	<10 ppm
Identification (IR)	Passes Test	Passes Test	Passes Test
Iron	≤ 3 ppm	<0.30 ppm	<0.30 ppm
Molarity	5.8 – 6.2M	6.0M	6.0M
pH	4.5 - 6.5	6.1 @ 23.1 °C	6.1 @ 23.1 °C

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: BSI-ATM-0001

INTENDED USE: Material represented by this Certificate of Analysis is suitable for use as an excipient. It is manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product or Household Item.

OVI STATEMENT: Based on the manufacturing process and the controlled handling, storage and analysis of this product, this product complies with the requirements and specifications listed in the current USP method <467> Tables 1, 2, 3, or 4.

Prepared by: *Jason Blyden* Date: 12/19/24 Job Title: QA Supervisor

Reviewed by: *David McCall* Date: 12/19/24 Job Title: QA Tech III

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying.